Skip to main content

Table 4 Adverse events ≥grade 3 in the mFOLFOX6 arm (n=50)

From: Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301)

  All grades Grade 3–4
n (%) n (%)
Laboratory findings
 Neutropenia 39 (78.0) 16 (32.0)
 Leukopenia 28 (56.0) 3 (6.0)
 Anemia 41 (82.0) 2 (4.0)
 Hypoalbuminemia 44 (88.0) 2 (4.0)
 Hyponatremia 18 (36.0) 2 (4.0)
 Increased AST 38 (76.0) 1 (2.0)
 Hypokalemia 14 (28.0) 1 (2.0)
 Hyperkalemia 12 (24.0) 1 (2.0)
Clinical findings
 Anorexia 25 (50.0) 2 (4.0)
Catheter related
 Infection 2 (4.0) 2 (4.0)
 Fatigue/malaise 23 (46.0) 1 (2.0)
 Nausea 21 (42.0) 1 (2.0)
 Diarrhea 21 (42.0) 1 (2.0)
 Vascular disorder 1 (2.0) 1 (2.0)
 Hyperglycemia 1 (2.0) 1 (2.0)
  1. AST: aspartate aminotransferase, mFOLFOX6: folinic acid, 5-FU, and oxaliplatin